

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 1 251 138 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
**23.10.2002 Bulletin 2002/43**

(51) Int Cl.7: **C07K 14/47, C12N 15/62,  
A61K 39/00**

(21) Application number: **01109707.8**

(22) Date of filing: **19.04.2001**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(71) Applicant: **Schärtl, Hermann, Dr.  
82140 Olching (DE)**

(72) Inventor: **Schärtl, Hermann, Dr.  
82140 Olching (DE)**

(74) Representative: **Schüssler, Andrea, Dr.  
Kanzlei Huber & Schüssler  
Truderinger Strasse 246  
81825 München (DE)**

### Remarks:

The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.

### (54) Prion protein dimers useful for vaccination

(57) Described is a prion protein, wherein said prion protein is a homodimer or heterodimer. The prion protein dimers are highly immunogenic capable of inducing an immune response in a mammal, thus useful for prophylactic or therapeutic vaccination against diseases associated with the infectious forms of prion proteins, PrP<sup>Sc</sup>, i.e. transmissible spongiform encephalopathies. More-

over, antibodies generated by using the prion protein dimers as an antigen, pharmaceutical composition containing the prion protein dimers or antibodies directed against said dimers as well as DNA sequences encoding the prion protein dimers are described.

EP 1 251 138 A1

**Description**

[0001] The present invention relates to a prion protein, wherein said prion protein is a homodimer or heterodimer. The prion protein dimers are highly immunogenic capable of inducing an immune response in a mammal, thus useful for prophylactic or therapeutic vaccination against diseases associated with the infectious forms of prion proteins, PrP<sup>Sc</sup>, i.e. transmissible spongiform encephalopathies. Furthermore, the present invention relates to antibodies generated by using the prion protein dimers as an antigen, pharmaceutical compositions containing the prion protein dimers or antibodies directed against said dimers as well as DNA sequences encoding the prion protein dimers.

[0002] Transmissible spongiform encephalopathies are neurodegenerative diseases such as scrapie of sheep, bovine spongiform encephalopathy (BSE) of cattle and Creutzfeldt-Jakob disease (CJD) of man. Infectious preparations derived from infected brains are resistant to ultraviolet and ionizing radiation as well as other procedures which normally inactivate nucleic acids indicating that nucleic acids are not required for infectivity. Purification of infectious preparations from brains revealed the presence of a protein required for infectivity. These experimental observations led to the "protein only" hypothesis which proposes that particular proteinaceous infectious particles (prions) are responsible for the transmission of transmissible spongiform encephalopathies (Prusiner et al., Proc. Natl. Acad. Sci. USA 95, 13363-13383 (1998)). Prions consist mainly of a protease resistant protein designated PrP<sup>Sc</sup> (prion protein, "Sc": scrapie), which is an abnormal Isoform of the proteinase K sensitive PrP<sup>C</sup> ("C":cellular). The prion protein PrP<sup>C</sup> is a species specific protein which is physiologically expressed in brain cells and peripheral blood cells as well as, e.g., in spleen. The biological function of PrP<sup>C</sup> is so far unknown. Transgenic mice which are no longer capable of expressing PrP<sup>C</sup> (PrP knock out mice) do not show any pathological damages and cannot be infected with prions (Bueler et al., Nature 356, 577-582 (1992); Bueler et al., Cell 73, 1339-1347 (1993)).

[0003] Both isoforms, PrP<sup>Sc</sup> and PrP<sup>C</sup>, share the same amino acid sequence, but differ in their secondary structure. Circular Dichroism (CD) and Fourier Transform Infrared (FTIR) spectroscopy revealed a significantly higher  $\beta$ -sheet content for PrP<sup>Sc</sup> as compared to a high  $\alpha$ -helix content in PrP<sup>C</sup>. It has been suggested that prion propagation involves the conversion of  $\alpha$ -helical domains in PrP<sup>C</sup> into  $\beta$ -sheets in PrP<sup>Sc</sup>. The *in vitro* conversion of PrP<sup>C</sup> into a PrP<sup>Sc</sup>-like molecule was demonstrated employing a proteinase K resistance assay.

[0004] It has been suggested that for the development of a transmissible spongiform encephalopathy the interaction of PrP<sup>Sc</sup> and PrP<sup>C</sup> is a crucial event, wherein PrP<sup>Sc</sup> forces a conversion of PrP<sup>C</sup> into the pathological conformation (PrP<sup>Sc</sup>). Accordingly, transgenic mice which are no longer capable of expressing PrP<sup>C</sup> (PrP knock out mice) are resistant to infections with PrP<sup>Sc</sup>. Although, the prion proteins of various species differ as regards their amino acid sequences, within the group of mammals there is a high homology (88 to 99%). Apparently, due to differences in the amino acid sequences the prion protein cannot be transmitted between certain species (relative or absolute species barrier). Due to the fact that the prion protein is a physiologically expressed protein, each species exhibits immunological tolerance via its own specific prion protein. Unfortunately, so far transmissible spongiform encephalopathies, e.g. BSE, are incurable. There is no therapy available for soothing the symptoms of the disease, let alone for stopping the disease, e.g. by vaccination.

[0005] Therefore, it is the object of the present invention to provide a vaccine for the prevention or treatment of a transmissible spongiform encephalopathy.

[0006] According to the invention this is achieved by the subject matters defined in the claims.

[0007] The present invention provides a prion protein, wherein said prion protein is a homodimer or heterodimer with the monomer corresponding to or comprising a prion protein according to the definition below. During the experiments leading to the present invention, it has, surprisingly, been found that prion protein dimers are useful for inducing an enhanced immune response against PrP<sup>C</sup> and PrP<sup>Sc</sup>. Using this apparent remarkable immunogenicity of the prion protein dimer it was even possible *in vivo* to generate antibodies directed against the homologous prion protein (i.e. mouse antibodies directed against murine PrP), thereby abolishing or by-passing the known auto-tolerance present within a given species. After incubation of cells permanently producing PrP<sup>Sc</sup> with the antibodies that were generated by immunization with the prion protein dimer for 16 hours a drastic inhibition of the *de novo* synthesis of PrP<sup>Sc</sup> could be observed. Presumably, this result is due to generation of a functional PrP<sup>C</sup> knock out state where the surface-located PrP<sup>C</sup> substrate needed for continuous cellular conversion into PrP<sup>Sc</sup> is functionally impaired, resulting finally in inhibition of generation of PrP<sup>Sc</sup>. It is known from the literature that the surface location of PrP<sup>C</sup> is a prerequisite for cellular prion conversion (Taraboulos et al., J. Cell Biol. 129, 121-132 (1995)). Even more, studies with transgenic mice have demonstrated that peripheral expression of PrP<sup>C</sup> is absolutely required for replication and transport of PrP<sup>Sc</sup> from peripheral sites of the body to the central nervous system (Blättler et al., Nature 389, 69-73 (1997)). In this respect it has been discovered by the inventors that after application of the prion protein dimer of the present application to a subject, the induced immune response results in the downregulation of the surface expression of PrP<sup>C</sup>. Accordingly, the conversion rate ( $\text{PrP}^C \Rightarrow \text{PrP}^Sc$ ) can be drastically reduced, thus, blocking the initiation and the progression of the disease. Thus, the prion protein dimers of the present invention are useful as a vaccine for the prevention or treatment of a transmissible spongiform encephalopathy.

[0008] Accordingly, the present invention relates to a prion protein, wherein said prion protein is a homodimer or heterodimer which can elicit an immune response against PrP<sup>C</sup> or PrP<sup>Sc</sup>, preferably an immune response which is higher compared to the immune response obtained using for vaccination the corresponding monomer. As used herein, the term "prion protein" comprises the native (full length and/or mature) protein as well as variants thereof, e.g. truncated versions, which are still useful for eliciting an enhanced immune response, i.e. still useful for vaccination. In this context, the term "protein" also comprises peptides or polypeptides having a length of at least 8, preferably of at least 15 and, more preferably, of at least 20 amino acids. The person skilled in the art knows sources for the prion protein monomers and DNA sequences encoding the prion protein monomers, respectively (Schätzl et al., J. Mol. Biol. 245, 362-374 (1995); Wopfner et al., J. Mol. Biol. 289, 1163-1178 (1999); sequences deposited at Genbank accessible via Public 10 Medline database). Furthermore, a person skilled in the art knows methods for coupling the monomers in order to obtain the dimer. Preferably, the monomers are covalently coupled.

[0009] In a preferred embodiment, the homodimer or heterodimer is a fusion protein comprising the monomeric prion protein units. Such a fusion protein can be generated by methods well known by the person skilled in the art. The selection of a particular method mainly depends on the length of the monomers, i.e. very short fusion proteins are 15 preferably chemically synthesized, e.g. by standard solid phase synthesis, whereas longer fusion proteins are preferably produced by expression of the corresponding DNA sequences in a suitable host and isolation/purification of the fusion protein from the host or the culture medium.

[0010] Generally, by means of conventional molecular biological processes (see, e.g., Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2<sup>nd</sup> edition Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) it is 20 not only possible to generate a DNA sequence encoding the desired fusion protein but, additionally, to introduce different mutations into the DNA sequence. One possibility is the production of deletion mutants in which DNA molecules are produced by continuous deletions from the 5'- or 3'-termini of the coding DNA sequence and that lead to the synthesis of proteins that are shortened accordingly. The person skilled in the art can easily check as to whether such prion 25 protein dimers containing shortened monomeric units are still useful as a vaccine, e.g. using the methods described in the examples, below. For the manipulation in prokaryotic cells by means of genetic engineering the DNA sequences can be introduced into plasmids allowing a mutagenesis or a modification of a sequence by recombination of DNA sequences. By means of conventional methods (cf. Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> edition, Cold Spring Harbor Laboratory Press, NY, USA) bases can be exchanged and natural or synthetic sequences can be added. Furthermore, manipulations can be performed that provide suitable cleavage sites or that 30 remove superfluous DNA or cleavage sites. If insertions, deletions or substitutions are possible, in vitro mutagenesis, primer repair, restriction or ligation can be performed. As analysis method usually sequence analysis, restriction analysis and other biochemical or molecular biological methods are used.

[0011] In a more preferred embodiment, the monomers of the fusion protein are linked via a peptide spacer. Suitable 35 peptide spacers, which preferably consist of non-polar and non-bulky amino acids, have a length below 20 residues, provide a certain flexibility, thereby avoiding e.g. cystein or prolin residues which can induce rigidity (or vice versa in cases when rigidity or induction of an orientation/turns are wanted). These spacers are known to the person skilled in the art and comprise for example AGAIGGA [HIV-1 protease; Kräusslich et al., Proc. Natl. Acad. Sci. USA, 88, 3212-3217 (1991)], SGGRGG [HIV gp41; Tan et al., Proc. Natl. Acad. Sci USA, 94, 12303-12308 (1991)], GSGGGGSGGGGS 40 [single chain T-cell receptor; Khandekar et al., J. Biol. Chem. 272, 32190-32197 (1997)] or (GGGGS)<sub>n=1-3</sub> [single chain antibodies; Kortt et al., Eur. J. Biochem. 221, 151-157 (1994)]. Examples of preferred spacers are (a) spacers having a length of 2 to 3 amino acids, wherein the DNA sequence encoding said spacer contains a restriction site, (b) oligomers composed of small neutral amino acids (e.g. Ala-Gly-Ala-Ile-Gly-Gly-Ala), or c) an oligomer having an amino acid sequence that defines an epitope, e.g. flag-tag, HA-epitope etc..

[0012] For the generation of the prion protein dimers encoding DNA sequences and for constructing expression 45 vectors which contain said DNA sequences, it is possible to use general methods known in the art. These methods include e.g. in vitro recombination techniques, synthetic methods and in vivo recombination methods as described in Sambrook et al., Molecular Cloning, A Laboratory Manual, 2<sup>nd</sup> edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, for example.

[0013] For recombinant production of the dimeric prion protein of the invention, the DNA sequences encoding said 50 protein are inserted into a suitable expression vector. Preferably, they are plasmids, cosmids, viruses, bacteriophages and other expression vectors usually used in the field of genetic engineering. Expression vectors suitable for use in the present invention include, but are not limited to e.g. pGEMEX, pUC derivatives, pGEX-2T, pET3b, T7 based expression vectors and pQE and pTrcHis (for expression in E.coli). For the expression in yeast, e.g. pY100 and Ycpad1 have to be mentioned while e.g. pCDNA3.1, pKCR, pEFBOS, cDM8, pMSCND, and pCEV4 have to be indicated for 55 the expression in animal cells. The baculovirus expression vector pAcSGHisNT-A is especially suitable for the expression in insect cells. The DNA sequences can also be contained in a recombinant virus containing appropriate expression cassettes. Suitable viruses that may be used in the present invention include baculovirus, SFV, vaccinia, sindbis virus, SV40, Sendai virus, adenovirus, an AAV virus or a parvovirus, such as MVM or H-1. The vector may also be a retrovirus,

such as MoMULV, MoMuLV, HaMuSV, MuMTV, RSV or GaLV. Preferably, the DNA sequence is operatively linked to the regulatory elements in the recombinant vector that guarantee the transcription and synthesis of an RNA in prokaryotic and/or eukaryotic cells that can be translated. The nucleotide sequence to be transcribed can be operably linked to a promoter like a T7, metallothionein I or polyhedrin promoter. For expression in mammals, the DNA sequences are 5 operatively linked to a suitable promoter like, e.g. a human cytomegalovirus "immediate early promoter" (pCMV).

[0014] Suitable host cells include bacteria, yeast, insect and animal cells, preferably mammalian cells. The *E. coli* strains HB101, DH1, x1776, JM101, JM109, BL21, XL1Blue and SG 13009, the yeast strain *Saccharomyces cerevisiae*, the insect cells sf9 and the animal cells L, A9, 3T3, FM3A, BHK, human SW13, CHO, COS, Vero and HeLa are preferred. Methods of transforming these host cells, of phenotypically selecting transformants and of expressing the DNA according to the invention by using the above described vectors are known in the art. For recombinant production of the dimeric prion protein of the invention, the host cell is cultivated under conditions allowing the synthesis of the protein and the protein is subsequently isolated from the cultivated cells and/or the culture medium. Isolation and purification of the recombinantly produced proteins may be carried out by conventional means including preparative chromatography and immunological separations involving affinity chromatography with monoclonal or polyclonal antibodies, e.g. 10 with the antibody A7 and 3F4 described in the examples, below.

[0015] In an alternative preferred embodiment the monomers of the dimeric prion protein of the invention are covalently coupled via suitable compounds, e.g. in such a way that the monomers are covalently linked via their C-termini or N-termini or via the C-terminus of one monomer and the N-terminus of the other monomer. Care has to be taken 15 that dimerization is carried out in such a way that eliciting an immune response by the dimeric protein is not adversely effected. Suitable compounds for dimerization are known to the person skilled in the art, preferably such a compound is a polyethyleneglycole, activated benzodiazepine, oxazolone, aminimide, azalactone, diketopiperazine or a monosaccharide. The corresponding chemical reactions are also known to the person skilled in the art.

[0016] The monomers of the dimeric prion protein of the present invention can be identical (homodimer: the monomers are derived from the same species) or different (heterodimer: the monomers are derived from different species). 20 In the case of the heterodimer it can be expected that an immune response against the own PrP<sup>C</sup> as well as the foreign PrP<sup>C</sup> is induced.

[0017] As already described above the dimeric prion protein of the present invention also includes monomers which are variants of the native prion protein monomers. Particularly preferred are variants which are N-terminally and/or C-terminally truncated proteins (monomers).

[0018] A preferred dimeric prion protein (and its corresponding nucleotide sequence) is shown in Fig. 5.

[0019] The present invention also relates to the use of a dimeric prion protein of the present invention for the production of polyclonal or monoclonal antibodies as well as to an antibody, preferably a monoclonal antibody which binds to the dimeric prion protein of the present invention. Such antibodies are useful for passive immunization and can be produced according to well known methods. The term "antibody", preferably, relates to antibodies which consist essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations. Monoclonal antibodies are made using as an antigen the dimeric prion protein of the invention by methods well known to those skilled in the art (see, e.g., Köhler et al., *Nature* 256 (1975), 495). As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')2 fragments) which are capable of specifically binding to protein. Fab and F(ab')2 fragments 35 lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., *J. Nucl. Med.* 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain (scFv), and humanized antibodies.

[0020] Moreover, the present invention also relates to DNA sequences encoding the dimeric prion proteins of the 40 present invention as well as an expression vector containing such a DNA sequence. Examples of such DNA sequences and suitable expression vectors are already described above. Such DNA sequences or expression vectors are not only useful for the recombinant production of the dimeric prion protein of the present invention but also useful as "genetic vaccine". For the preparation of a genetic vaccine, the DNA sequences of the invention are inserted into an appropriate vector under the control of a suitable promoter, e.g. a vector or promoter as described above. Additional suitable vectors are, e.g., herpes simplex virus type 1 amplicon or recombinant Semliki forest virus vectors, plus-strand RNA virus vectors (lentiviral vectors), minus-strand RNA virus vectors (e.g. Rabies virus, RSV). In this connection also "gene gun" applications are suitable. A vaccine according to the present invention can be used to stimulate humoral and/or cellular immune response in subjects who may benefit from such responses by protection against or treatment 45 of a transmissible spongiform encephalopathy.

[0021] Finally, the present invention relates to a pharmaceutical composition comprising a dimeric prion protein, an antibody, DNA sequence or an expression vector of the present invention in a pharmaceutically acceptable carrier. After application to the subject, the immune response induced should result in the downregulation of the surface expression of PrP<sup>C</sup>. Accordingly, the transport of infectious prions from peripheral sites of inoculation (e.g. oral or i.v.) to 50

the central nervous system as well as the initial peripheral replication should be significantly impaired. In addition, the conversion rate ( $\text{PrP}^C \Rightarrow \text{PrP}^{Sc}$ ) can be drastically reduced, thus blocking the progression of the disease. Thus, the compounds of the present invention are useful for the preparation of a vaccine for the prevention or treatment of a transmissible spongiform encephalopathy (prophylactic or therapeutic vaccination). For the preparation of the vaccine the purified compounds described above may be combined with any suitable adjuvant such as ISCOMS, alum, Freund's Incomplete or Complete Adjuvant, Quil A and other saponins or any other adjuvant as described in the literature. Suitable doses and routes of administration depend on the particular compound and are well known to the person skilled in the art.

10 Brief description of the drawings

Figure 1: PrP dimer

[0022] Coomassie blue staining after purification showing a purity of > 90%. M, molecular weight standards.

15 Figure 2: Characterization of the PrP dimer using CD

[0023] The results show that the PrP monomer and the PrP dimer have a similar or even identical secondary structure.

20 Figure 3

(a) Immunological responses in different mice

25 [0024] Immunization with the PrP monomer and PrP dimer, respectively. Recombinant murine PrP was separated on a SDS PAGE gel, subsequently transferred to a PVDF membrane and the immunoblots were probed with decreasing concentrations auf mice antisera. The immunization with the PrP dimer resulted in an enhanced antibody production.

(b) Immunological responses in different rabbits

30 [0025] Immunization with the PrP monomer and PrP dimer, respectively. Recombinant PrP monomer ( $\text{PrP}_M$ ) and PrP dimer ( $\text{PrP}_D$ ), respectively, were separated on a SDS PAGE gel, subsequently transferred to a PVDF membrane and the immunoblots were probed with anti- $\text{PrP}_{\text{monomer}}$  and anti- $\text{PrP}_{\text{dimer}}$ , respectively. The immunization with the PrP dimer resulted in an enhanced antibody production.

35 Figure 4: In vitro experiments using  $\text{PrP}^{Sc}$  infected cells

40 [0026] During incubation with antibodies for 16 hours proteins were metabolically labeled using  $^{35}\text{S}$ -methionine and subsequently immunoprecipitated (RIPA). Prior to the RIPA the cell lysates were separated into two fractions for digestion with proteinase K (+/-) and separated into soluble and insoluble fractions using ultracentrifugation (1 hour, 100,000 x g, 1% sarcosyl); data only shown for the insoluble fraction. Only after incubation with A7 a drastic decrease of the *de novo* synthesis of  $\text{PrP}^{Sc}$  can be observed. A,B: after deglycosylation using PNGase F; K: without incubation with antibodies; P: preimmune serum; 3F4: monoclonal antibody directed against the 3F4 epitope of the prion protein; A7: antibody obtained from rabbits which had been immunized with the PrP dimer.

45 Figure 5: Translation of hisPrPDPc (1-1320)

[0027]

Underlined in the first line: His-Tag

50 Underlined in the middle: Linker

[0028] The present invention is explained by the examples.

**Example 1****Generation of a fusion protein (dimer) comprising two prion protein monomers covalently linked by a peptide linker**

**[0029]** Mouse genomic DNA encoding the prion protein (murine PrP-A, derived from murine N2a neuroblastoma cell line; for sequence see Schätzl et al, 1995, supra; Wopfner et al., 1999, supra) was amplified by polymerase chain reaction (PCR) using the following primer pairs which introduce a peptide linker (Ala-Gly-Ala-Ile-Gly-Gly-Ala) encoding sequence containing a Pvul restriction site; primer pair I: 5'-GCG GAT CCG TCG CCA CCA TGG CGA ACC TTG GCT A-3' (PrPB+1) and 5'-ACC GAT CGC TCC AGC GCT GGA TCT TCT CCC GTC GTA AT-3' (231+L new); primer pair II: 5'-AGC GAT CGG TGG AGC TAA AAA GCG GCC AAA GCC TGG AG-3' (23+L new); 5'-ATC TAG ATC ATC ATC CCA CGA TCA GGA AGA-3' (254 PX) (the DNA sequence encoding the Pvul restriction site is underlined). For the introduction of an N-terminal His-tag, the removal of the N-terminal and C-terminal signal peptides and the introduction of additional restriction sites, a second PCR was carried out using the following primers: 5'-GAT GTT GGA TCC TGC AAG AAG CGG CCA AAG-3' (5'-primer, the BamHI-site is underlined.); 5'-GGA GGA GAT CCA GCA GCT AGA AGC TTT TC-3' (3'-primer, the HindIII-site is underlined.) The PCR fragment obtained (c.f. Fig. 5) was inserted into the pQE30 expression vector (Qiagen, Hilden, DE). In order to obtain higher yields of the recombinantly produced protein, proteinase deficient bacteria (BL21, Stratagene Europe, Amsterdam, The Netherlands) were used for expression. Four hours after induction of expression using 2 mM IPTG, bacteria were lysed in 6 M guanidine hydrochloride (6 M guanidine hydrochloride, 20 mM sodium phosphate, 500 mM sodium chloride, pH 7.8), cell debris were pelleted by centrifugation (20 min., 10,000 x g), the supernatant was loaded on a Ni<sup>2+</sup> loaded SP-HiTrap column (Amersham Pharmacia, Uppsala, Sweden) which had been previously equilibrated using binding buffer (8 M urea, 20 mM sodium phosphate, 500 mM sodium chloride, pH 7.8) and incubated. The column was washed for several times (8 M urea, 20 mM sodium phosphate, 500 mM sodium chloride, 80 mM imidazole, pH 6.3) and, subsequently, the fusion protein containing the His-tag was eluted using 8 M urea, 20 mM sodium phosphate, 500 mM sodium chloride, 500 mM imidazole, pH 6.3. Fractions of the eluate were collected. The fractions showing the highest protein concentration were pooled and for removal of urea dialyzed against pure water (Slide-A-Lyzer, Pierce, Bonn, DE). As shown in Figure 1, the protein could be obtained with a very high purity. As shown in Figure 2, the secondary structure of the purified renatured dimer is similar (or even identical) to the secondary structure of the prion protein monomer.

**Example 2****Immunization of mice and rabbits**

**[0030]** Ten female B6D<sub>2</sub>F<sub>1</sub> (B57BL/6 x DBA) mice (inbred strain generated at the Institute of Molecular Animal Breeding/Gene Center Munich, DE; six weeks old) were immunized by subcutaneous injections of 50 µg of the protein dimer described in Example 1 and a control monomer, respectively (monomer: murine PrP23-231 verus dimer: murine PrP23-231=23-231 [connected by the linker sequence], both with the 3F4 epitope and an N-terminal poly-histidine tag). At day 0 the proteins were combined with Freund's Complete Adjuvant, for boosting (at day 21 and day 42, respectively) the proteins were combined with Freund's Incomplete Adjuvant. Ten days after the last immunization blood samples for antibody evaluation were taken. It could be shown that the application of the prion protein monomer (control) resulted in the generation of a lower amount of specific antibodies compared to the application of the prion protein dimer. After application of the dimer about 50% of mice showed a pronounced accumulation of specific antibodies (Figure 3a). The induced specific polyclonal immune response was measured in immunoblot. Recombinant murine PrP23-231 was separated on SDS-PAGE, transferred to PVDF membranes and incubated in an Immunoblot analysis with serial dilutions of sera of immunized mice (primary antibody). The pre-immune sera were used to eliminate background signals. Staining was accomplished using conjugated secondary antibodies (antimouse) and the enhanced chemiluminescence kit (ECL plus, Amersham Corp., Buckinghamshire, U.K.). The mice immunized with PrP dimer showed higher antibody titers. Dilutions beyond 1:3000 still resulted in detectable signals. This finding indicates that the used immunogen was capable of overcoming the auto-tolerance phenomenon known for species-identical prion proteins. Further data showed that the induced antibodies were not directed against the N-terminal fusion domain or the linker sequence being reactive against authentic murine PrP23-231.

**[0031]** A similar result could already be achieved using rabbits, i.e. the rabbits immunized with the prion protein dimer showed a stronger immune response compared to the rabbits immunized with the prion protein monomer (Figure 3b). Recombinant monomeric and dimeric prion proteins (PrPM and PrPD, respectively, which were used also as immunogens in immunization) were separated on SDS-PAGE, transferred to PVDF membranes and analyzed in immunoblot. The left panel shows incubation with the serum from the rabbit immunized with PrP monomer, the right panel from the rabbit immunized with PrP dimer. Staining was accomplished using conjugated anti-rabbit secondary antibodies and

the ECL plus kit. Whereas the left panel shows mainly a reaction against the monomeric PrP, the right panel demonstrates a much stronger immune reactivity which is directed against monomeric and dimeric prion protein.

### Example 3

5

#### **The application of antibodies generated by immunization with a prion protein dimer leads to inhibition of the de novo synthesis of PrP<sup>Sc</sup> in vitro**

10

[0032] The biological relevance of the immunization experiments described in Example 2 could be verified by the following in vitro experiment. ScMHM2 cells [cultured murine neuroblastoma cells (ATCC CCL 131); persistently infected with RML prions; stably transfected with a 3F4-tagged PrP; c.f. Schätzl et al., J. Virol. 71, 8821-8831, (1997)] which are infected with the infectious version of the prion protein (PrP<sup>Sc</sup>) and permanently produce PrP<sup>Sc</sup> were incubated with different types of antibodies. Incubation was carried using (a) commercially available monoclonal antibodies (3F4) (Signet Pathology Systems, Dedham, MA, USA) which are directed against an epitope of the prion protein produced in ScMHM2 cells and (b) the antiserum obtained from rabbits immunized with the prion protein dimer described in Example 1. During incubation with antibodies for 16 hours proteins were metabolically labeled using <sup>35</sup>S-methionine and subsequently immunoprecipitated (RIPA). Prior to the RIPA the cell lysates were separated into two fractions for digestion with proteinase K (+/-) and separated into soluble and insoluble fractions using ultracentrifugation (1 hour, 100,000 x g, 1% sarcosyl). As shown in Figure 4, after incubation with the prion protein dimer for 16 hours a drastic inhibition of the *de novo* synthesis of PrP<sup>Sc</sup> could be observed. The results observed with the 3FA antibody are less pronounced. It can be concluded that this result is due to generation of a functional PrP<sup>c</sup> knock out state on the cell surface and, accordingly, an inhibition of the generation of PrP<sup>Sc</sup>. These results demonstrate in living cells that the induced anti-PrP antibodies are capable of binding to surface-located authentic PrP<sup>c</sup> under native conditions (proof of principle for interaction with surface-located PrP under native conditions). Even more, bound antibodies are apparently internalised with PrP<sup>c</sup> demonstrating a high binding affinity (resulting in an insoluble PrP of full length which is PK sensitive, see full-length signal in Fig. 4A, lanes 5-8). Finally, endogenous PrP<sup>Sc</sup> biogenesis was heavily impaired resulting in no more *de novo* generated PK resistant PrP<sup>Sc</sup> (Fig. 4B, lanes 7 and 8). The biological effect on PrP<sup>Sc</sup> biogenesis is therefore demonstrated as well (proof of principle for impairment of prion biogenesis). The efficiency of this principle could also be shown by using particular chemical compounds: The functional removal of surface-PrP<sup>c</sup> resulted in a reduction of the production of prion proteins.

15

20

25

30

35

40

45

50

55

## SEQUENCE LISTING

5           <110> Dr. Schätzl, Herrmann

<120> Prion protein dimers

<130> S1044

10           <140> EP 01109707.8

<141> 2001-04-19

<160> 15

<170> PatentIn Ver. 2.1

15           <210> 1

<211> 1320

<212> DNA

<213> Artificial Sequence

20           <220>

<223> Description of Artificial Sequence:

fusion protein

<220>

<221> CDS

25           <222> (1)..(1317)

<400> 1

atg aga gga tcg cat cac cat cac cat cac gga tcc tgc aag aag cgg Met Arg Gly Ser His His His His His His Gly Ser Cys Lys Lys Arg	48
1                                 5                                 10                                 15	15

cca aag cct gga ggg tgg aac act ggc gga agc cga tac cct ggg cag Pro Lys Pro Gly Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln	96
20                                 25                                 30	30

ggg agc cct gga ggc aac cgt tac cca cct cag ggt ggc acc tgg ggg Gly Ser Pro Gly Gly Asn Arg Tyr Pro Pro Gln Gly Gly Thr Trp Gly	144
35                                 40                                 45	45

cag ccc cac ggt ggc tgg gga caa ccc cat ggg ggc agc tgg gga Gln Pro His Gly Gly Trp Gly Gln Pro His Gly Gly Ser Trp Gly	192
50                                 55                                 60	60

caa cct cat ggt ggt agt tgg ggt cag ccc cat ggc ggt gga tgg ggc Gln Pro His Gly Gly Ser Trp Gly Gln Pro His Gly Gly Trp Gly	240
65                                 70                                 75                                 80	80

caa gga ggg ggt acc cac aat cag tgg aac aag ccc agt aag cca aaa Gln Gly Gly Thr His Asn Gln Trp Asn Lys Pro Ser Lys Pro Lys	288
85                                 90                                 95	95

acc aac atg aag cac atg gcc ggc gct gct gcg qca ggg gcc gtg gtg Thr Asn Met Lys His Met Ala Gly Ala Ala Ala Gly Ala Val Val	336
100                                 105                                 110	110

ggg ggc ctt ggt ggc tac atg ctg ggg agt gcc atg agc agg ccc atg Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Met	384
115                                 120                                 125	125

atc cat ttt ggc aac gac tgg gag gac cgc tac tac cgt gaa aac atg Ile His Phe Gly Asn Asp Trp Glu Asp Arg Tyr Tyr Arg Glu Asn Met	432
130                                 135                                 140	140

## EP 1 251 138 A1

	tac cgc tac cct aac caa gtg tac tac agg cca gtg gat cag tac agc Tyr Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr Ser 145 150 155 160	480
5	aac cag aac aac ttc gtg cac gac tgc gtc aat atc acc atc aag cag Asn Gln Asn Asn Phe Val His Asp Cys Val Asn Ile Thr Ile Lys Gln 165 170 175	528
10	cac acg gtc acc acc acc aag ggg gag aac ttc acc gag acc gat His Thr Val Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp 180 185 190	576
15	gtg aag atg atg gag cgc gtg gag cag atg tgc gtc acc cag tac Val Lys Met Met Glu Arg Val Val Glu Gln Met Cys Val Thr Gln Tyr 195 200 205	624
20	cag aag gag tcc cag gcc tat tac gac ggg aga aga tcc agc gct gga Gln Lys Glu Ser Gln Ala Tyr Tyr Asp Gly Arg Arg Ser Ser Ala Gly 210 215 220	672
25	gct atc ggt gga gct aaa aag cgg cca aag cct gga ggg tgg aac act Ala Ile Gly Gly Ala Lys Lys Arg Pro Lys Pro Gly Gly Trp Asn Thr 225 230 235 240	720
30	ggc gga agc cga tac cct ggg cag ggc agc cct gga ggc aac cgt tac Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly Asn Arg Tyr 245 250 255	768
35	cca cct cag ggt ggc acc tgg ggg cag ccc cac ggt ggt ggc tgg gga Pro Pro Gln Gly Thr Trp Gly Gln Pro His Gly Gly Trp Gly 260 265 270	816
40	caa ccc cat ggg ggc agc tgg gga caa cct cat ggt ggt agt tgg ggt Gln Pro His Gly Ser Trp Gly Gln Pro His Gly Gly Ser Trp Gly 275 280 285	864
45	cag ccc cat ggc ggt gga tgg ggc caa gga ggg ggt acc cac aat cag Gln Pro His Gly Gly Trp Gly Gln Gly Gly Thr His Asn Gln 290 295 300	912
50	tgg aac aag ccc aat aag cca aaa acc aac atg aag cac atg gcc ggc Trp Asn Lys Pro Asn Lys Pro Lys Thr Asn Met Lys His Met Ala Gly 305 310 315 320	960
55	gct gct gcg gca ggg gcc gtg gtg ggg ggc ctt ggt ggc tac atg ctg Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly Tyr Met Leu 325 330 335	1008
	ggg agc gcc atg agc agg ccc atg atc cat ttt ggc aac gac tgg gag Gly Ser Ala Met Ser Arg Pro Met Ile His Phe Gly Asn Asp Trp Glu 340 345 350	1056
	gac cgc tac tac cgt gaa aac atg tac cgc tac cct aac caa gtg tac Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr Pro Asn Gln Val Tyr 355 360 365	1104
	tac agg cca gtg gat cag tac agc aac cag aac aac ttc gtg cac gac Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn Phe Val His Asp 370 375 380	1152
	tgc gtc aat atc acc atc aag cag cac acg gtc acc acc acc acc aag Cys Val Asn Ile Thr Ile Lys Gln His Thr Val Thr Thr Thr Lys 385 390 395 400	1200

ggg gag aac ttc acc gag acc gat gtg aag atg atg gag cgc gtg gtg Gly Glu Asn Phe Thr Glu Thr Asp Val Lys Met Met Glu Arg Val Val	1248
405 410 415	
5 gag cag atg tgc gtc acc cag tac cag aag gag tcc cag gcc tat tac Glu Gln Met Cys Val Thr Gln Tyr Gln Lys Glu Ser Gln Ala Tyr Tyr	1296
420 425 430	
10 gac ggg aga aga tcc agc agc tag Asp Gly Arg Arg Ser Ser Ser	1320
435	

15 <210> 2  
 <211> 439  
 <212> PRT  
 <213> Artificial Sequence

20 <220>  
 <223> Description of Artificial Sequence:

fusion protein

<400> 2

25 Met Arg Gly Ser His His His His His Gly Ser Cys Lys Lys Arg 1 5 10 15
---

Pro Lys Pro Gly Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln 20 25 30
---

30 Gly Ser Pro Gly Gly Asn Arg Tyr Pro Pro Gln Gly Gly Thr Trp Gly 35 40 45
--

Gln Pro His Gly Gly Trp Gly Gln Pro His Gly Gly Ser Trp Gly 50 55 60
---

35 Gln Pro His Gly Gly Ser Trp Gly Gln Pro His Gly Gly Trp Gly 65 70 75 80
---

Gln Gly Gly Gly Thr His Asn Gln Trp Asn Lys Pro Ser Lys Pro Lys 85 90 95
---

40 Thr Asn Met Lys His Met Ala Gly Ala Ala Ala Gly Ala Val Val 100 105 110
---

Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Met 115 120 125
--

45 Ile His Phe Gly Asn Asp Trp Glu Asp Arg Tyr Tyr Arg Glu Asn Met 130 135 140
---

Tyr Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr Ser 145 150 155 160
--

50 Asn Gln Asn Asn Phe Val His Asp Cys Val Asn Ile Thr Ile Lys Gln 165 170 175
---

His Thr Val Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp 180 185 190
--

55 Val Lys Met Met Glu Arg Val Val Glu Gln Met Cys Val Thr Gln Tyr 195 200 205
---

Gln Lys Glu Ser Gln Ala Tyr Tyr Asp Gly Arg Arg Ser Ser Ala Gly  
 210 215 220  
 Ala Ile Gly Gly Ala Lys Lys Arg Pro Lys Pro Gly Gly Trp Asn Thr  
 5 225 230 235 240  
 Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly Asn Arg Tyr  
 245 250 255  
 Pro Pro Gln Gly Gly Thr Trp Gly Gln Pro His Gly Gly Trp Gly  
 10 260 265 270  
 Gln Pro His Gly Gly Ser Trp Gly Gln Pro His Gly Gly Ser Trp Gly  
 275 280 285  
 Gln Pro His Gly Gly Trp Gly Gln Gly Gly Thr His Asn Gln  
 15 290 295 300  
 Trp Asn Lys Pro Asn Lys Pro Lys Thr Asn Met Lys His Met Ala Gly  
 305 310 315 320  
 Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly Gly Tyr Met Leu  
 20 325 330 335  
 Gly Ser Ala Met Ser Arg Pro Met Ile His Phe Gly Asn Asp Trp Glu  
 340 345 350  
 Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr Pro Asn Gln Val Tyr  
 25 355 360 365  
 Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn Asn Phe Val His Asp  
 370 375 380  
 Cys Val Asn Ile Thr Ile Lys Gln His Thr Val Thr Thr Thr Lys  
 30 385 390 395 400  
 Gly Glu Asn Phe Thr Glu Thr Asp Val Lys Met Met Glu Arg Val Val  
 405 410 415  
 Glu Gln Met Cys Val Thr Gln Tyr Gln Lys Glu Ser Gln Ala Tyr Tyr  
 35 420 425 430  
 Asp Gly Arg Arg Ser Ser Ser  
 435  
  
 40 <210> 3  
 <211> 7  
 <212> PRT  
 <213> Artificial Sequence  
  
 45 <220>  
 <223> Description of Artificial Sequence:  
 peptide spacer  
  
 50 <400> 3  
 Ala Gly Ala Ile Gly Gly Ala  
 5  
  
 55 <210> 4  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:

peptide spacer

Ser Gly Gly Arg Gly Gly  
5

10

<210> 5  
<211> 17  
<212> PRT  
<213> Artificial Sequence

15

<220>  
<223> Description of Artificial Sequence:

peptide spacer

20

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Gly

Ala

```
<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence
```

30

<220>  
<223> Description of Artificial Sequence:

peptide spacer

35

<400> 6

Gly Gly Gly Gly Ser  
5

40

<210> 7  
<211> 10  
<212> PRT  
<213> Artificial Sequence

40

<220>  
<223> Description of Artificial Sequence:

### peptide spacer

<400> 7

50

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
5 10

5



**Primer**

&lt;400&gt; 12

5                   agcgatcggt ggagctaaaa agcggccaaa gcctggag                   38

&lt;210&gt; 13

&lt;211&gt; 33

10                  &lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:

15                  **Primer**

&lt;400&gt; 13

20                   atctagatca tcatcatccc acgatcagga aga

33

&lt;210&gt; 14

&lt;211&gt; 30

&lt;212&gt; DNA

25                  &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:

**Primer**

30                  &lt;400&gt; 14

35                   gatgttggat cctgcaagaa gcggccaaag

30

&lt;210&gt; 15

&lt;211&gt; 29

&lt;212&gt; DNA

40                  &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:

**Primer**

45                  &lt;400&gt; 15

45                   ggaggagatc cagcagctag aagcttttc

29

**Claims**

- 50                  1. A prion protein, wherein said prion protein is a homodimer or heterodimer.
2. The prion protein of claim 1, wherein the monomers of the homodimer or heterodimer are covalently coupled.
3. The prion protein of claim 2, wherein the homodimer or heterodimer is a fusion protein comprising the monomers.
4. The prion protein of claim 3, wherein the monomers of the fusion protein are linked via a peptide spacer.

5. The prion protein of claim 4, wherein the peptide spacer is (a) a spacer having a length of 2 to 3 amino acids, wherein the DNA sequence encoding said spacer contains a restriction site or (b) an oligomer composed of small neutral amino acids or c) an oligomer having an amino acid sequence that defines an epitope.
- 5      6. The prion protein of claim 1 or 2, wherein the monomers are covalently coupled via polyethyleneglycole, activated benzodiazepine, oxazolone, azalactone, dикетопіперазін or a monosaccharide.
- 10     7. The prion protein of any one of claims 1 to 6, wherein the monomers are derived from the same or different species.
- 10     8. The prion protein of any one of claims 1 to 7, wherein the monomers comprise the native prion protein or a variant thereof.
- 15     9. The prion protein of claim 8, wherein the variant is a N-terminally and/or C-terminally truncated prion protein.
- 15     10. Use of a prion protein according to any one of claims 1 to 9 for the production of a polyclonal or monoclonal antibody.
- 20     11. An antibody which specifically binds to a prion protein according to any one of claims 1 to 9.
- 20     12. The antibody of claim 11 which is a monoclonal antibody.
- 25     13. A DNA sequence encoding the prion protein of any one of claims 1 to 9.
- 25     14. An expression vector containing a DNA sequence of claims 13.
- 30     15. A pharmaceutical composition containing a prion protein according to any one of claims 1 to 9, an antibody of claim 11 or 12, a DNA sequence of claim 13 or an expression vector of claim 14.
- 30     16. Use of a prion protein according to any one of claims 1 to 9, an antibody of claim 11 or 12, a DNA sequence of claim 13 or an expression vector of claim 14 for the preparation of a vaccine for the prevention or treatment of a transmissible spongiform encephalopathy.

35

40

45

50

55

Fig. 1




Fig. 2




Fig. 3a

rekombinant PrP ▶




Fig. 3b




Fig. 4




Fig. 5

Translation of hisPrPDPcr(1-1320)

Universal code

Total amino acid number: 439, MW=48163

Max ORF: 1-1317, 439 AA, MW=48163

```

1      ATGAGAGGATCGCATCACCATCACGGATCCTGCAAGAAGCGGCCAAAGCCTGGA
1      M R G S H H H H H G S C K K R P K P G

61      GGGTGGAACACTGGCGGAAGCCGATAACCTGGCAGGGGAGCCCTGGAGGCAACCGTTAC
21      G W N T G G S R Y P G Q G S P G G N R Y

121     CCACCTCAGGGTGGCACCTGGGGCAGCCCCACGGTGGCTGGGACAACCCATGGG
41      P P Q G G T W G Q P H G G G W G Q P H G

181     GGCAGCTGGGGACAACCTCATGGTGGTAGTTGGGTCAAGCCCCATGGCGGTGGATGGGC
61      G S W G Q P H G G S W G Q P H G G G W G

241     CAAGGAGGGGTACCCACAATCAGTGGAACAAAGCCCAGTAAGCCAAAAACCAACATGAAG
81      Q G G G T H N Q W N K P S K P K T N M K

301     CACATGGCCGGCGCTGCTCGGCAGGGGCCGTGGTGGGGGCTTGGTGGCTACATGCTG
101     H M A G A A A A G A V V G G L G G Y M L

361     GGGAGTGCCATGAGCAGGCCATGATCCATTGGCAACGACTGGGAGGACCGCTACTAC
121     G S A M S R P M I H F G N D W E D R Y Y

421     CGTAAAACATGTACCGCTACCTAACCAAGTGTACTACAGGCCAGTGGATCAGTACAGC
141     R E N M Y R Y P N Q V Y Y R P V D Q Y S

481     AACCAAGAACAACTTCGTGCACGACTGCGTCAATATCACCATCAAGCAGCACACGGTCACC
161     N Q N N F V H D C V N I T I K Q H T V T

541     ACCACCAAGGGGAGAACTCACCGAGACCGATGTGAAGATGATGGAGCGCGTGGTG
181     T T T K G E N F T E T D V K M M E R V V

601     GAGCAGATGTGCGTCACCCAGTACCAAGAAGGAGTCCCAGGCCTATTACGACGGGAGAAGA
201     E Q M C V T Q Y Q K E S Q A Y Y D G R R

661     TCCAGCGCTGGAGCGATCGGTGGAGCTAAAAGCGGCCAAAGCCTGGAGGGTGGAACACT
221     S S A G A I G G A K K R P K P G G W N T

721     GGCGGAAGCCGATAACCTGGCAGGGCAGCCCTGGAGGCAACCGTTACCCACCTCAGGGT
241     G G S R Y P G Q G S P G G N R Y P P Q G

781     GGCACCTGGGGCAGCCCCACGGTGGTGGCTGGGACAACCCATGGGGCAGCTGGGA
261     G T W G Q P H G G G W G Q P H G G G S W G

841     CAACCTCATGGTGGTAGTTGGGTCAAGCCCCATGGCGGTGGATGGGCCAAGGAGGGGT
281     Q P H G G S W G Q P H G G G W G Q G G G

901     ACCCACAAATCAGTGGAACAAAGCCAATAAGCCAAAAACCAACATGAAGCACATGGCCGC
301     T H N Q W N K P N K P K T N M K H M A G

961     GCTGCTGCGGCAGGGGCCGTGGTGGGGGCTTGGTGGCTACATGCTGGGAGCGCCATG
321     A A A A G A V V G G L G G Y M L G S A M

1021    AGCAGGCCATGATCCATTGGCAACGACTGGGAGGACCGCTACTACCGTGAAAACATG
341     S R P M I H F G N D W E D R Y Y R E N M

```

1081 TACCGCTACCCTAACCAAGTGTACTACAGGCCAGTGGATCAGTACAGCAACCAGAACAAAC  
361 Y R Y P N Q V Y Y R P V D Q Y S N Q N N  
  
1141 TTCGTGCACGACTGCGTCAATATCACCATCAAGCAGCACACGGTCACCACCACCAAG  
381 F V H D C V N I T I K Q H T V T T T T K  
  
1201 GGGGAGAACTTCACCGAGACCGATGTGAAGATGATGGAGCGCGTGGAGCAGATGTGC  
401 G E N F T E T D V K M M E R V V E Q M C  
  
1261 GTCACCCAGTACCAAGAAGGAGTCCCAGGCCTATTACGACGGGAGAAGATCCAGCAGCTAG  
421 V T Q Y Q K E S Q A Y Y D G R R S S S \*



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 01 10 9707

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)						
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim							
X	PRIOLA S.A. ET AL.: "A 60-kDa Prion Protein (PrP) with properties of both the normal and scrapie-associated forms of PrP*" J. BIOL. CHEM., vol. 270, no. 7, 17 February 1995 (1995-02-17), pages 3299-3305, XP002178941 * the whole document *	1,2,7,8, 10-16	C07K14/47 C12N15/62 A61K39/00						
A	HARMEYER S ET AL.: "Synthetic peptide vaccines yield monoclonal antibodies to cellular and pathological prion proteins of ruminants." J. GENERAL VIROL., vol. 79, 1998, pages 937-945, XP002178942 * the whole document *	3-6  1-16							
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)						
			C07K A61K C12N						
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>1 October 2001</td> <td>Galli, I</td> </tr> </table>				Place of search	Date of completion of the search	Examiner	THE HAGUE	1 October 2001	Galli, I
Place of search	Date of completion of the search	Examiner							
THE HAGUE	1 October 2001	Galli, I							
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone      Y : particularly relevant if combined with another document of the same category      A : technological background      O : non-written disclosure      P : intermediate document</p> <p>T : theory or principle underlying the invention      E : earlier patent document, but published on, or after the filing date      D : document cited in the application      L : document cited for other reasons      &amp; : member of the same patent family, corresponding document</p>									

